【个人简介】

周燕玲，中国共员，医学博士，副主任医师，硕士研究生导师，广州医科大学附属脑科医院儿少科和早期干预科副主任，快速抗抑郁中心负责人。兼任中华精神医学会精神医学分会委员，广东省心理卫生协会儿少心理卫生专委会副主委，广东省脑科学应用学会理事，广东省临床医学学会临床心身医学和心理治疗委员会委员，广州市医学会精神医学分会常务委员。

【研究方向】

青少年抑郁症早期识别及早期干预，氯胺酮及神经调控快速治疗抑郁症新技术研究。

【科研项目】

1．国家自然科学基金面上项目，82471546，氯胺酮改善抑郁的“外周-中枢Crosstalk”新机制：调控脂肪酸代谢增加PrL神经元兴奋性，2025/01-2028/12，49万元，在研，主持。

2．广州医科大学大学生科研创新能力提升项目，睡眠节律对大学生认知功能和脑功能 的影响：一项fMRI研究，2024/01-2025/12，5万元，在研，项目指导老师。

3．广东省大学生创新创业训练计划项目，外周犬尿氨酸代谢在氯胺酮抗抑郁作用中的机制研究，2023/06-2024/05，5万元，在研，项目指导老师。

4．广州医科大学大学生科研创新能力提升项目，外周犬尿氨酸代谢在氯胺酮抗抑郁作用中的机制研究，2022/07-2024/06，5万元，在研，项目指导老师。

5．广东省自然科学基金面上项目，2022A1515011567，基于功能连接的个体化精准靶点rTMS治疗伴NSSI青少年抑郁症及脑网络机制研究，2022/01-2024/12，10万元，在研，主持。

6．广州市科技计划项目立项，202201010714，氯胺酮抑郁NLRP3炎性小体活性调控巨噬细胞/小胶质细胞M2型极化的抗抑郁机制研究，2022/01-2024/12，5万元，结题，主持。

7．广东省自然科学基金面上项目，2019A1515011366，基于“犬尿氨酸-谷氨酸”通路探讨氯胺酮抗抑郁的作用机制，2019/10-2022/09，10万元，结题，主持。

8．国家自然科学基金青年项目，81801343，BDNF介导的海马神经重塑在氯胺酮治疗抑郁-疼痛共病中的作用研究，2019/01-2021/12，21万元，结题，主持。

9．国家重点研发计划精准医学研究专项(课题二)，2016YFC0906302，针对难治型抑郁症使用新型药物氯胺酮（ketamine）进行抗抑郁治疗的探索性研究，2016/07-2020/12,130万元，结题，参与（第二参与人）。

10．广州市科技计划项目立项，201607010131，高剂量利培酮维持治疗精神分裂症减量后复发风险及功能的随访研究，2016/04-2018/03，20万元，结题，主持。

【代表性论文及著作】

1.Wang C, Lan X, Liu W, Zhan Y, Zheng W, Chen X, Liu G, Mai S, Lu H, McIntyre RS, Zhou Y*, Ning Y*. Non-improvement predicts subsequent non-response to repeated-dose intravenous ketamine for depression: a re-analysis of a 2-week open-label study in patients with unipolar and bipolar depression. Transl Psychiatry. 2024 Aug 6;14(1):324.

2.Zhang M, Li W, Ye Y, Hu Z, Zhou Y*, Ning Y*. Efficacy and safety of intermittent theta burst stimulation on adolescents and young adults with major depressive disorder: A randomized, double blinded, controlled trial. J Affect Disord. 2024 Apr 1;350:214-221.

3.Liu H, Wang C, Lan X, Li W, Zhang F, Hu Z, Ye Y, Ning Y*, Zhou Y*. Functional connectivity of the amygdala subregions and the antidepressant effects of repeated ketamine infusions in major depressive disorder. Eur Psychiatry. 2024 Apr 4:1-28.

4.Zeng Y, Li W, Chen X, You Z, Mai S, Lan X, Ning Y*, Zhou Y*. Mediating effect of inflammation on the relationship between sleep disruption and suicidal ideation in major depressive disorder. J Affect Disord. 2024 May 1;352:371-378.

5.Liu G, Li Z, Lin S, Luo Z, Yin Y, Zhou Y*, Ning Y*. NEFA can serve as good biological markers for the diagnosis of depression in adolescents. J Affect Disord. 2024 May 1;352:342-348.

6.Lan X, Liu H, Wang C, Li W, Zhang F, Hu Z, Chen X, You Z, Ning Y*, Zhou Y*. Sex differences in the effects of repeated ketamine infusions on bone markers in patients with unipolar and bipolar depression. Biol Sex Differ. 2024 Jan 29;15(1):12.

7.Liang Y, You Z, Chen X, Liu G, Li W, Wang C, Lan X, Luo Z, Mai S, Zhang F, Zeng Y, Chen Y, Chen Y, Ning Y*, Zhou Y*. Long-term quality of life after repeated ketamine infusions in anxious and nonanxious patients with depression. J Affect Disord. 2024 Jan 9;349:394-399.

8.Luo Z, Li W, Zhang F, Hu Z, You Z, Wang C, Lan X, Mai S, Chen X, Zeng Y, Chen Y, Liang Y, Chen Y, Zhou Y*, Ning Y*. Altered regional brain activity moderating the relationship between childhood trauma and depression severity. J Affect Disord. 2024 Jan 18:S0165-0327(24)00178-2.

9.Zhang M, Li W, Ye Y, Hu Z, Zhou Y*, Ning Y*. Efficacy and safety of intermittent theta burst stimulation on adolescents and young adults with major depressive disorder: A randomized, double blinded, controlled trial. J Affect Disord. 2024 Jan 8;350:214-221.

10.Zhou Y, Chen X, Ning Y. Repeated infusions of ketamine for treatment-resistant bipolar depression in real-world practice. Bipolar Disord. 2023 Sep;25(6):515-516.

11.Li W, Hu Z, Wang C, Lan X, Zhang M, Zhang F, You Z, Ye Y, Liu H, Luo Z, Zeng Y, Chen Y, Chen Y, Wu K, Lao G, Chen J, Li G, Zhou Y*, Ning Y*. Altered Reward Circuit Function Moderates the Relationship between Childhood Maltreatment and Depression Severity in Adolescents. Depression and Anxiety, 2023, 4084004.

12.Zeng Y, Sun B, Zhang F, Hu Z, Li W, Lan X, Ning Y*, Zhou Y*. The core inflammatory factors in patients with major depressive disorder: a network analysis. Front Psychiatry. 2023 Aug 25;14:1216583.

13.Lan X, Wang C, Zhang F, Liu H, Li W, Ye Y, Hu Z, Mai S, Ning Y*, Zhou Y*. Short-term cognitive effects of repeated-dose esketamine in adolescents with major depressive disorder and suicidal ideation: a randomized controlled trial. Child Adolesc Psychiatry Ment Health. 2023 Sep 14;17(1):108.

14.You Z, Wang C, Lan X, Li W, Shang D, Zhang F, Ye Y, Liu H, Zhou Y*, Ning Y*. The contribution of polyamine pathway to determinations of diagnosis for treatment-resistant depression: A metabolomic analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2023 Sep 1;128:110849.

15.Hu Z, Li W, Ye Y, Zhang F, Liu H, Wang C, Lan X, Chen X, You Z, Lan Y, Ning Y*, Zhou Y*. Alterations of functional connectivity in young people with depression mediate the relationship between sleep quality and cognitive function. J Affect Disord. 2023 Aug 7:S0165-0327(23)01002-9.

16.Zhou Y, Lan X, Wang C, Zhang F, Liu H, Fu L, Li W, Ye Y, Hu Z, Chao Z, Ning Y*. Effect of Repeated Intravenous Esketamine on Adolescents With Major Depressive Disorder and Suicidal Ideation: A Randomized Active-Placebo-Controlled Trial. J Am Acad Child Adolesc Psychiatry. 2023 Jul 1:S0890-8567(23)00373-8.

17.Lan X, Wang C, Zhang F, Liu H, Fu L, Li W, Ye Y, Hu Z, Mai S, Ning Y*, Zhou Y*. Efficacy of repeated intravenous esketamine in adolescents with anxious versus non-anxious depression. Gen Psychiatr. 2023 Jun 21;36(3):e101007.

18.Zeng Y, Zhang F, Liu H, Li W, Ning Y*, Zhou Y*. Psychotic symptoms and neurocognition among patients with major depressive disorder: A chained mediation model of depressive symptoms and socio-occupational functioning. J Affect Disord. 2023 Jul 1;332:194-200.

19.Liu H, Wang C, Lan X, Li W, Zhang F, Fu L, Ye Y, Ning Y*, Zhou Y*. Functional connectivity of the amygdala and the antidepressant and antisuicidal effects of repeated ketamine infusions in major depressive disorder. Front Neurosci. 2023 Feb 2;17:1123797.

20.Wu Z, Gan Y, Li N, Lan X, Wang C, Zhang F, Liu H, Li W, Ye Y, Hu Z, Ning Y, Zhou Y*. Pain mediates the improvement of social functions of repeated intravenous ketamine in patients with unipolar and bipolar depression. J Affect Disord. 2023 May 6;334:152-158.

21.Zhang F, Wang C, Lan X, Li W, Ye Y, Liu H, Hu Z, You Z, Zhou Y*, Ning Y*. Ketamine-induced hippocampal functional connectivity alterations associated with clinical remission in major depression. J Affect Disord. 2023 Mar 15;325:534-541.

22.Liu H, Lan X, Wang C, Zhang F, Fu L, Li W, Ye Y, Hu Z, Chao Z, Ning Y*, Zhou Y*. The efficacy and safety of esketamine in the treatment of major depressive disorder with suicidal ideation: study protocol for a randomized controlled trial. BMC Psychiatry. 2022 Nov 30;22(1):744.

23.Ye Y, Wang C, Lan X, Li W, Fu L, Zhang F, Liu H, Zhang Z, Wu K, Zhou Y*, Ning Y*. Abnormal amygdala functional connectivity in MDD patients with insomnia complaints. Psychiatry Res Neuroimaging. 2023 Jan;328:111578.

24.Lan X, Wu F, Wang C, Wu K, Fang Z, Lao G, Zhang B, Ning Y*, Zhou Y*. Sex differences in the association of plasma cytokines and neurocognition in first-episode major depressive disorder. J Affect Disord. 2023 Feb 1;322:258-266.

25.Lan X, Wang C, Li W, Chao Z, Lao G, Wu K, Li G, Ning Y, Zhou Y*. The association between overweight/obesity and poor cognitive function is mediated by inflammation in patients with major depressive disorder. J Affect Disord. 2022 Sep 15;313:118-125.

26.Li W, Wang C, Lan X, Fu L, Zhang F, Ye Y, Liu H, Zhou Y*, Ning Y*. Resting-state functional connectivity of the amygdala in major depressive disorder with suicidal ideation. J Psychiatr Res. 2022 Sep;153:189-196.

27.Li W, Wang C, Lan X, Fu L, Zhang F, Ye Y, Liu H, Wu K, Zhou Y*, Ning Y*. Variability and concordance among indices of brain activity in major depressive disorder with suicidal ideation: A temporal dynamics resting-state fMRI analysis. J Affect Disord. 2022 Sep 6;319:70-78.

28.Ye Y, Wang C, Lan X, Li W, Fu L, Zhang F, Liu H, Wu K, Zhou Y*, Ning Y*. Baseline patterns of resting functional connectivity within posterior default-mode intranetwork associated with remission to antidepressants in major depressive disorder. Neuroimage Clin. 2022 Oct 14;36:103230.

29.Zhou Y, Wang C, Lan X, Zheng W, Li H, Chao Z, McIntyre RS*, Ning Y*. The effectiveness of repeated intravenous ketamine on subjective and objective psychosocial function in patients with treatment-resistant depression and suicidal ideation. J Affect Disord. 2022 May 1;304:78-84.

30.Li W, Wang C, Lan X, Fu L, Zhang F, Ye Y, Liu H, Wu K, Lao G, Chen J, Li G, Zhou Y*, Ning Y*. Aberrant Dynamic Functional Connectivity of Posterior Cingulate Cortex Subregions in Major Depressive Disorder With Suicidal Ideation. Front Neurosci. 2022 Jul 19;16:937145.

31.Zhou Y, Wang C, Lan X, Li W, Chao Z, Wu K, McIntyre RS*, Ning Y*. Cognitive Function Mediates the Anti-suicide Effect of Repeated Intravenous Ketamine in Adult Patients With Suicidal Ideation. Front Psychiatry. 2022 May 2;13:779326.

32.Zhou Y, Zhang Z, Wang C, Lan X, Li W, Zhang M, Lao G, Wu K, Chen J, Li G, Ning Y*. Predictors of 4-week antidepressant outcome in patients with first-episode major depressive disorder: An ROC curve analysis. J Affect Disord. 2022 May 1;304:59-65.

33.Lan X#, Zhou Y#, Wang C, Li W, Zhang F, Liu H, Fu L, Wu K, McIntyre RS*, Ning Y*. Pre-treatment Pain Symptoms Influence Antidepressant Response to Ketamine in Depressive Patients. Front Psychiatry. 2022 Mar 16;13:793677.

34.Zhou Y, Wu F, Lan X, Li H, Chao Z, Ning Y*. Plasma Inflammatory Cytokines and Treatment-resistant Depression with Comorbid Pain: Improvement by Ketamine. Journal of Neuroinflammation. 2021.18:200.

35.Zhou Y, Wang C, Lan X, Zheng W, Li H, Chao Z, Wu K, Roger S. McIntyre*, Ning YP*. The Potential Pro-cognitive Effects with Intravenous Subanesthetic Ketamine in Adults with Treatment-Resistant Major Depressive or Bipolar Disorders and Suicidality. J Psychiatr Res. 2021 Dec;144:312-319.

36.Zhou Y, Wu F, Wang C, Zheng W, Lan X, Deng X, Ning Y*. Relationship between hippocampal volume and inflammatory markers following six infusions of ketamine in major depressive disorder. J Affect Disord. 2020. 276: 608-615.

37.Zhou Y, Wu F, Liu W, Zheng W, Wang C, Zhan Y, Lan X, Ning Y*. Volumetric changes in subcortical structures following repeated ketamine treatment in patients with major depressive disorder: a longitudinal analysis. Transl Psychiatry. 2020. 10(1): 264.

38.Zhou Y, Liu W, Wang C, Zheng W, Lan X, Weng S, Ning Y*. Cardiovascular effects of repeated subanaesthetic ketamine infusion in depression. J Psychopharmacol. 2021 Feb;35(2):159-167.

39.Zhou Y, Liu W, Zheng W, Wang C, Zhan Y, Lan X, Zhang B, Zhang C, Ning Y*. Predictors of response to repeated ketamine infusions in depression with suicidal ideation: An ROC curve analysis. Journal of Affective Disorders. 2020, 264, 263–271.

40.Zhou Y, Zheng W, Liu W, Wang C, Zhan Y, Li H, Chen L, Ning Y*. Cross-sectional relationship between kynurenine pathway metabolites and cognitive function in major depressive disorder. Psychoneuroendocrinology. 2019,101, 72-79.

41.Zhou Y, Zheng W, Liu W, Wang C, Zhan Y, Li H, Chen L, Li M, Ning Y*. Antidepressant effect of repeated ketamine administration on kynurenine pathway metabolites in patients with unipolar and bipolar depression. Brain, behavior, and immunity, 2018, 74, 205-212.

42.Zhou Y, Zheng W, Liu W, Wang C, Zhan Y, Li H, Chen L, Li M, Ning Y*. Neurocognitive effects of six ketamine infusions and the association with antidepressant response in patients with unipolar and bipolar depression. Journal of psychopharmacology. 2018;32(10):1118-1126.

43.Zhou Y, Li G, Li D, Cui H, Ning Y*. Dose Reduction of Risperidone and Olanzapine Can Improve Cognitive Function and Negative Symptom in Stable Schizophrenic Patients: A Single-blinded, 52-week, Randomized Controlled Study. Journal of Psychopharmacology. 2018, 33(4),494-501.

44.Zhou Y，Rosenheck R，Mohamed S，Ning Y，He H*. Factors associated with complete discontinuation of medication among patients with schizophrenia in the year after hospital discharge. Psychiatry Res. 2017, 250:129-135.

45.Zhou Y, Ning Y, Rosenheck R, Sun B, Zhang J, Ou Y, He H*. Effect of living with patients on caregiver burden of individual with schizophrenia in China. Psychiatry Res. 2016,245,230-237.

46.Zhou Y, Rosenheck R, Mohamed S, Ou Y, Ning Y, He H*. Comparison of burden among family members of patients diagnosed with schizophrenia and bipolar disorder in a large acute psychiatric hospital in China. BMC Psychiatry. 2016, 16(1), 283.

47.Zhou Y, Rosenheck R, Mohamed S, Zhang J, Chang Q, Ou Y, Sun B, Ning Y, He H*. Insight in inpatients with schizophrenia: relationship to symptoms and neuropsychological functioning. Schizophr Res. 2015. 161(2-3): 376-81.

48.He H, Ning Y, Rosenheck R, Sun B, Zhang J, Zhou Y*. Is severity of family burden a correlate of length of stay. Psychiatry Res. 2015. 230(1): 84-9.

49.Zhou Y, Rosenheck RA, He H*. Health insurance in China: variation in co-payments and psychiatric hospital utilization.J Ment Health Policy Econ. 2014. 17(1): 25-32.

50.Zhou Y, Ning Y, Fan N, Mohamed S, Rosenheck RA, He H*. Correlates of readmission risk and readmission days in a large psychiatric hospital in Guangzhou, China. Asia Pac Psychiatry. 2014.6(3): 342-9.

【所获荣誉和奖励】

被评为广州市医学骨干人才、广州市卫生健康委优秀人才、广州好医生、羊城好医生。